Drug intelligence / Profile preview

Biokine Advance

Development stage: Unknown
Lead developer: Adamas Biotech
Modality: Small Molecules
Administration: Oral

Overview

Biokine Advance is a green tea catechin-based nutraceutical developed by Adamas Biotech. It is currently being evaluated in clinical trials for the treatment of Irritable Bowel Syndrome (IBS), Lower Urinary Tract Symptoms (LUTS), and Prostate Cancer. The product leverages the bioactive properties of green tea polyphenols, particularly catechins like epigallocatechin gallate (EGCG), which are thought to provide therapeutic benefits through antioxidant, anti-inflammatory, and potentially anti-proliferative mechanisms. It is being developed as a supportive or therapeutic approach for managing urinary and prostate symptoms as well as gastrointestinal distress.

Brand names: Biokine Advance
Other names: Biokine Advance IBSBiokine Advance LUTS

Beyond the preview

Go deeper on Biokine Advance.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biokine Advance.

Explore the full profile